We found that there were only marginally statistically significant differences in clinical efficacy and toxic effects between patients aged under 70 years and those aged 70 years or above.
← all excerpts
Effect and safety of immunotherapy among elder patients (age ≥ 65) with recurrent or metastatic nasopharyngeal carcinoma.
1
—
—